PharmaDeals acquired by IMS Health

Acquirers of pharmaceutical and life sciences data assets underwrite three things: the depth of the historical record, the renewal behaviour of the subscriber base, and how directly the dataset plugs into an existing analytics product. Historical depth is the hardest of the three to replicate — a database holding 16 years of licensing and M&A records cannot be rebuilt at speed, and that irreplaceability is what converts a data business from a revenue line into a strategic asset. Low subscriber concentration and predictable renewals reduce perceived risk and support a stronger multiple. In the PharmaDeals transaction, IMS Health was buying a transaction and licensing layer that its competitive intelligence suite did not otherwise have.

Subscription data businesses are usually valued on a multiple of annual recurring revenue rather than EBITDA, adjusted for renewal rate, revenue concentration, gross margin, and the cost of maintaining the dataset. Where the underlying data is proprietary and accumulates over time, a scarcity premium sits on top of the revenue multiple, because the acquirer is buying a position that cannot be competed away quickly. A generalist advisor working from an EBITDA benchmark will typically understate this. A competitive sell-side process run by an M&A advisor with sector fluency is the most reliable way to establish a defensible valuation and prevent a first offer from anchoring the negotiation.

Buy rather than build is the default in commercial intelligence, because a dataset's value is a function of how long it has been collected and that is the one input capital cannot accelerate. UK specialist data businesses are attractive to US and European healthcare analytics groups for practical reasons as well: English-language records that travel into export markets, proximity to the Oxford, Cambridge, and London life sciences clusters where much of the deal flow originates, and valuations that are frequently more attractive than equivalent US assets. IMS Health acquired several specialist datasets in the years around 2012, including SDI Health, Forcea, and Healthcare Data Solutions, as part of exactly this strategy.

In a carve-out, an acquirer is underwriting separability as much as performance. They will test which customer contracts transfer cleanly, which staff move with the asset, what shared systems and premises have to be replicated, and how long any transitional services arrangement with the vendor needs to run. Every dependency left unresolved at heads of terms becomes a price adjustment or an indemnity later. Vendors who map the separation before going to market — rather than discovering it during due diligence — hold the valuation they opened with. This was the central piece of preparation in the sale of PharmaDeals out of PharmaVentures.

Confidentiality discipline matters more in a divestment than in a whole-company sale, because the vendor still has to trade afterwards. A targeted process approaching a small, verified group of strategic acquirers exposes far less than a broad auction, and staged disclosure keeps commercially sensitive information about the retained business out of the data room entirely. Internally, the practical constraint is management time: the same people usually run both the asset being sold and the business being kept. An advisor who absorbs buyer communication, coordinates the legal and financial workstreams, and holds the timetable protects the trading performance that the valuation depends on.

Timing in life sciences is driven by the acquirer's cycle as much as the founder's. Consolidation in commercial intelligence, diagnostics, and services runs in waves, and the window in which several well-capitalised buyers are competing for the same category is usually two to three years wide. Selling into that window with a management team able to operate without the founder on every call produces a materially different outcome from selling after it closes. On the business side, the readiness tests are consistent recurring revenue, documented IP and data ownership, and clean contract assignment provisions. Founders who wait until growth has plateaued or until they are worn out by the business tend to realise less.

Three recur across the Oxford, Cambridge, and Golden Triangle clusters. The first is key-person dependency: businesses built around a founder's scientific or commercial reputation carry a discount until the client and subscriber relationships demonstrably sit with the organisation. The second is IP and data provenance — where a business has grown through university collaboration, grant funding, or licensed inputs, acquirers will test ownership line by line, and unresolved chain-of-title issues surface at the worst moment in due diligence. The third is buyer concentration: the credible acquirer universe for a specialist life sciences asset is often fewer than a dozen organisations worldwide, most of them overseas, which makes the quality of the advisor's access to those specific buyers more consequential than the size of their general network.

Three tests separate advisors in this category. First, valuation fluency: can they build and defend a case based on recurring revenue, data scarcity, and IP rather than defaulting to an EBITDA multiple. Second, named buyer access: ask which specific acquirers they have transacted with in your sub-sector, not how many deals they have completed overall. Third, independence — an advisor without audit, tax, or other service line relationships with the same counterparties has no competing interest in where the deal lands. CapEQ is a Certified B Corporation, independently assessed against standards that include putting client outcomes ahead of deal income, and is a dedicated sell-side M&A boutique for UK founder-led businesses in the £5m–£100m revenue range.